Metastatic breast cancer: Endocrine therapy landscape reshaped.

about

Metastatic breast cancer: Endocrine therapy landscape reshaped.

Item

http://www.wikidata.org/entity/Q45072397

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@en

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@nl

type

Item

label

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@en

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@nl

prefLabel

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@en

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@nl

P1476

Metastatic breast cancer: Endocrine therapy landscape reshaped.

@en

P2093

Mohamad Adham Salkeni

http://www.w3.org/2001/XMLSchema#string

Samantha June Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Combination anastrozole and fulvestrant in metastatic breast cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies

Breast carcinoma in men: a population-based study

Whole-genome analysis informs breast cancer response to aromatase inhibition

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

P304

144-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/AJM.AJM_20_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29119080

http://www.w3.org/2001/XMLSchema#string

P932

5655644

http://www.w3.org/2001/XMLSchema#string